Royalty Pharma plc

**Signal Note: Eventide Initiates $50.2M RPRX Position** Eventide's entry into Royalty Pharma signals confidence in RPRX's diversified royalty cash flow model as a defensive biotech holding, likely appealing to their values-based mandate given the company's focus on established, FDA-approved therapies rather than speculative development-stage risk. The $50.2M position (1.3M shares) represents a meaningful new allocation, suggesting the fund sees attractive risk-adjusted returns from RPRX's stable, predictable revenue streams across its 180+ royalty interests. Without disclosed specifics, the timing may reflect valuation attractiveness or upcoming portfolio rebalancing rather than a catalyst-driven event.